Abstract
Tumor necrosis factor-α (TNF) has been identified as the most important mediator of septic shock and cachexia in animals and humans. Moreover, TNF plays a major role in the pathophysiological events of many other infectious and immunological diseases. Therefore, drugs interfering with the formation of TNF may have beneficial effects in these clinical circumstances.
Chapter PDF
Similar content being viewed by others
Keywords
- Tumor Necrosis Factor
- Renal Transplant Recipient
- Cerebral Malaria
- Endotoxin Shock
- Cytokine Release Syndrome
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Dinarello C (1989) Interleukin 1 and its biologically related cytokines. Adv Immunol 44:153–162
Schade FU, Burmeister I, Elekes E, Egel R, Wolter DT (1989) Mononuclear phagocytes and eicosanoids: aspects of their synthesis and biological activities. Blut 59:475–479
Spengler RN, Spengler ML, Lincoln P, Remick DG, Strieter RM, Kunkel SL (1989) Dynamics of dibutyryl cyclic AMP and prostaglandin E2-mediated suppression of lipopolysaccharide-induced tumor necrosis factor alpha gene expression. Infect Immun 57:2837–2844
Porter JM, Cutler BS, Lee BY (1982) Pentoxifylline efficacy in the treatment of intermittant claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 104:66–72
Schade FU (1990) Pentoxifylline increases survival in endotoxin shock and decreases TNF formation. Circ Shock 31:171–181
Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J, Kunkel SL (1988) Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 155:1230–1236
Waage A, Sorensen M, Stordal B (1990) Differential effect of oxpentyfylline on tumor necrosis factor and interleukin-6 production. Lancet 335:543
Schade FU, Schönharting MM (1986) Effect of pentoxifylline on the endotoxininduced shock reaction. Clin Hemorheol 6:462–468
Schade FU, von der Bosch J, Schönharting MM (1988) Increase of survival rate by pentoxifylline in endotoxin shock. In: Mandell GL, Nowick WJ (eds) Pentoxifylline and leukocyte function. Hoechst Roussel Pharmaceuticals, Somerville, pp 175–183
Schade FU, von der Bosch J, Schönharting MM (1989) Pentoxifylline increases survival of mice in endotoxin shock. In: Schrör K, Sinzinger H (eds) Prostaglandins in clinical research. Liss, New York, pp 223–227
Zabel P, Wolter DT, Schönharting MM, Schade UF (1989) Oxpentifylline in endotoxaemia. Lancet 1334:1474–1477
Michie HR, Manogue KR, Spriggs DR et al (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1418–1426
Dinarello CA (1987) The biology of interleukin-1 and comparison to tumor necrosis factor. Immunol Lett 16:227–232
Tannenbaum CS, Hamilton TA (1989) Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J Immunol 142:1274–1280
Ferran C, Sheehan K, Schreiber R, Bach JF, Chatenoud L (1991) Anti-TNF abrogates the cytokine-related anti-CD-3 induced syndrome. Transplant Proc 23:849–854
Gaston SG, Deierhoi MH, Patterson T (1991) OKT3 first dose reaction: association with T cell subsets and cytokine release. Kidney Int 39:141–146
Zabel P, Leimenstoll G, Schröder P, Elfeldt R, Schlaak M, Niedermayer W (1991) Pentoxifylline suppresses OKT3-induced tumor necrosis factor alpha formation in renal transplant recipients. Z Tx Med 3:62–65
Schandene P, Vandenbussche P, Crusiaux A et al (1992) Differential effects of pentoxyfylline on the production of tumor necrosis factor-alpha and interleukin-6 by monocytes and T-cells. Immunology 76:30–34
Alegre ML, Gastaldello K, Abromowicz D et al (1991) Pentoxyfylline reduces anti-CD3 monoclonal antibodies-induced cytokine release syndrome. Transplantation 52:674–690
Tracey JK, Lowry SF, Cerami A (1988) Cachectin: a hormone that triggers acute shock and chronic cachexia. J Infect Dis 157:413–420
Zabel P, Greinert U, Entzian P, Schlaak M (1992) Effects of pentoxifylline on circulating cytokines (TNF and IL-6) in severe pulmonary tuberculosis. Eur Cytokine Network 3:248A
Holler E, Kolb HJ, Möller A et al (1990) Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Blood 75:1011–1016
Bianco AJ, Appelbaum FR, Nemunaitis J et al (1991) Phase I–II trial of pentoxyfylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 78:1205–1211
Berens KL, Luke DR (1990) Pentoxifylline in the isolated perfused rat kidney. Transplantation 49:876–879
Welsh CH, Lien D, Wothen GS, Weil JV (1988) Pentoxifylline decreases endotoxin-induced pulmonary neutrophil sequestration and extravascular protein accumulation in the dog. Am Rev Respir Dis 138:1106–1114
Coccia MT, Waxman K, Soliman MH, Tominaga G. Pinderski L (1989) Pentoxifylline improves survival following hemorrhagic shock. Crit Care Med 17:36–38
Schönharting MM, Schade FU (1989) The effect of pentoxifylline in septic shock–new pharmacological aspects of an established drug. J Med 20:97–105
Zabel P, Schönharting MM, Schade FU, Schlaak M (1991) Effects of pentoxifylline in endotoxaemia in human volunteers. In: Sturck A (ed) Bacterial endotoxins, cytokine mediators and new therapies for sepsis. Wiley-Liss, New York, pp 207–213
Fazely F, Dezube BJ, Allen-Ryan J, Pardee AB, Ruprecht RM (1991) Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T-cells. Blood 77:1653–1656
Beutler B, Cerami A (1987) Cachectin: more than a tumor necrosis factor. N Engl J Med 316:379–382
Dezube BJ, Fridovich-Keil JL, Bouvard I, Lange RF, Pardee AB (1990) Oxpentifylline and well being in patients with cancer. Lancet 335:662
Kern P, Hemmer CJ, von Damme J, Gruss HJ, Dietrich M (1989) Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med 87:139–143
Sharief MK, Hentges R (1991) Association between tumor necrosis factor alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467–472
Kremsner PG, Grundmann H, Neifer S, Sliwa K, Sahlmüller G, Hegenscheid B, Blenzie U (1991) Pentoxyfylline prevents murine cerebral malaria. J Infect Dis 164:605–608
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schade, F.U., Zabel, P. (1994). Modulating Effects of Pentoxifylline on Cytokine Release Syndromes. In: Reinhart, K., Eyrich, K., Sprung, C. (eds) Sepsis. Update in Intensive Care and Emergency Medicine, vol 18. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85036-3_29
Download citation
DOI: https://doi.org/10.1007/978-3-642-85036-3_29
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-85038-7
Online ISBN: 978-3-642-85036-3
eBook Packages: Springer Book Archive